1
|
Eichhoff OM, Stoffel CI, Käsler J, Briker L, Turko P, Karsai G, Zila N, Paulitschke V, Cheng PF, Leitner A, Bileck A, Zamboni N, Irmisch A, Balazs Z, Tastanova A, Pascoal S, Johansen P, Wegmann R, Mena J, Othman A, Viswanathan VS, Wenzina J, Aloia A, Saltari A, Dzung A, Aebersold R, Ak M, Al-Quaddoomi FS, Albert SI, Albinus J, Alborelli I, Andani S, Attinger PO, Bacac M, Baumhoer D, Beck-Schimmer B, Beerenwinkel N, Beisel C, Bernasconi L, Bertolini A, Bodenmiller B, Bonilla X, Bosshard L, Calgua B, Casanova R, Chevrier S, Chicherova N, Coelho R, D'Costa M, Danenberg E, Davidson N, Drãgan MA, Dummer R, Engler S, Erkens M, Eschbach K, Esposito C, Fedier A, Ferreira P, Ficek J, Frei AL, Frey B, Goetze S, Grob L, Gut G, Günther D, Haberecker M, Haeuptle P, Heinzelmann-Schwarz V, Herter S, Holtackers R, Huesser T, Immer A, Irmisch A, Jacob F, Jacobs A, Jaeger TM, Jahn K, James AR, Jermann PM, Kahles A, Kahraman A, Koelzer VH, Kuebler W, Kuipers J, Kunze CP, Kurzeder C, Lehmann KV, Levesque M, Lischetti U, Lugert S, Maass G, Manz MG, Markolin P, Mehnert M, Mena J, Metzler JM, Miglino N, Milani ES, Moch H, Muenst S, Murri R, Ng CK, Nicolet S, Nowak M, Lopez MN, Pedrioli PG, Pelkmans L, Piscuoglio S, Prummer M, Rimmer N, Ritter M, Rommel C, Rosano-González ML, Rätsch G, Santacroce N, Del Castillo JS, Schlenker R, Schwalie PC, Schwan S, Schär T, Senti G, Shao W, Singer F, Sivapatham S, Snijder B, Sobottka B, Sreedharan VT, Stark S, Stekhoven DJ, Tanna T, Theocharides AP, Thomas TM, Tolnay M, Tosevski V, Toussaint NC, Tuncel MA, Tusup M, Van Drogen A, Vetter M, Vlajnic T, Weber S, Weber WP, Wegmann R, Weller M, Wendt F, Wey N, Wicki A, Wildschut MH, Wollscheid B, Yu S, Ziegler J, Zimmermann M, Zoche M, Zuend G, Krauthammer M, Schreiber SL, Hornemann T, Distel M, Snijder B, Dummer R, Levesque MP. ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma. Cancer Res 2023; 83:1128-1146. [PMID: 36946761 DOI: 10.1158/0008-5472.can-22-1826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Revised: 10/04/2022] [Accepted: 01/24/2023] [Indexed: 03/23/2023]
Abstract
Clinical management of melanomas with NRAS mutations is challenging. Targeting MAPK signaling is only beneficial to a small subset of patients due to resistance that arises through genetic, transcriptional, and metabolic adaptation. Identification of targetable vulnerabilities in NRAS-mutated melanoma could help improve patient treatment. Here, we used multiomics analyses to reveal that NRAS-mutated melanoma cells adopt a mesenchymal phenotype with a quiescent metabolic program to resist cellular stress induced by MEK inhibition. The metabolic alterations elevated baseline reactive oxygen species (ROS) levels, leading these cells to become highly sensitive to ROS induction. In vivo xenograft experiments and single-cell RNA sequencing demonstrated that intratumor heterogeneity necessitates the combination of a ROS inducer and a MEK inhibitor to inhibit both tumor growth and metastasis. Ex vivo pharmacoscopy of 62 human metastatic melanomas confirmed that MEK inhibitor-resistant tumors significantly benefited from the combination therapy. Finally, oxidative stress response and translational suppression corresponded with ROS-inducer sensitivity in 486 cancer cell lines, independent of cancer type. These findings link transcriptional plasticity to a metabolic phenotype that can be inhibited by ROS inducers in melanoma and other cancers. SIGNIFICANCE Metabolic reprogramming in drug-resistant NRAS-mutated melanoma cells confers sensitivity to ROS induction, which suppresses tumor growth and metastasis in combination with MAPK pathway inhibitors.
Collapse
Affiliation(s)
- Ossia M Eichhoff
- Department of Dermatology, University of Zurich, University Hospital Zurich, Zurich, Switzerland
| | - Corinne I Stoffel
- Department of Dermatology, University of Zurich, University Hospital Zurich, Zurich, Switzerland
| | - Jan Käsler
- Department of Dermatology, University of Zurich, University Hospital Zurich, Zurich, Switzerland
| | - Luzia Briker
- Department of Dermatology, University of Zurich, University Hospital Zurich, Zurich, Switzerland
| | - Patrick Turko
- Department of Dermatology, University of Zurich, University Hospital Zurich, Zurich, Switzerland
| | - Gergely Karsai
- Institute for Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland; Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich, Switzerland
| | - Nina Zila
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - Verena Paulitschke
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - Phil F Cheng
- Department of Dermatology, University of Zurich, University Hospital Zurich, Zurich, Switzerland
| | | | - Andrea Bileck
- Joint Metabolome Facility, Faculty of Chemistry, University of Vienna, Vienna, Austria
- Department of Analytical Chemistry, University of Vienna, Vienna, Austria
| | - Nicola Zamboni
- Institute for Molecular Systems Biology, ETH Zurich, Switzerland
| | - Anja Irmisch
- Department of Dermatology, University of Zurich, University Hospital Zurich, Zurich, Switzerland
| | - Zsolt Balazs
- Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland
- Biomedical Informatics, University Hospital of Zurich, Zurich, Switzerland
| | - Aizhan Tastanova
- Department of Dermatology, University of Zurich, University Hospital Zurich, Zurich, Switzerland
| | - Susana Pascoal
- St. Anna Children's Cancer Research Institute, Vienna, Austria
| | - Pål Johansen
- Department of Dermatology, University of Zurich, University Hospital Zurich, Zurich, Switzerland
| | - Rebekka Wegmann
- Institute for Molecular Systems Biology, ETH Zurich, Switzerland
| | - Julien Mena
- Institute for Molecular Systems Biology, ETH Zurich, Switzerland
| | - Alaa Othman
- Institute for Molecular Systems Biology, ETH Zurich, Switzerland
| | | | - Judith Wenzina
- Skin and Endothelium Research Division, Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - Andrea Aloia
- Institute for Molecular Systems Biology, ETH Zurich, Switzerland
| | - Annalisa Saltari
- Department of Dermatology, University of Zurich, University Hospital Zurich, Zurich, Switzerland
| | - Andreas Dzung
- Department of Dermatology, University of Zurich, University Hospital Zurich, Zurich, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Michael Krauthammer
- Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland
- Biomedical Informatics, University Hospital of Zurich, Zurich, Switzerland
| | | | - Thorsten Hornemann
- Institute for Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland; Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich, Switzerland
| | - Martin Distel
- St. Anna Children's Cancer Research Institute, Vienna, Austria
| | - Berend Snijder
- Institute for Molecular Systems Biology, ETH Zurich, Switzerland
| | - Reinhard Dummer
- Department of Dermatology, University of Zurich, University Hospital Zurich, Zurich, Switzerland
| | - Mitchell P Levesque
- Department of Dermatology, University of Zurich, University Hospital Zurich, Zurich, Switzerland
| |
Collapse
|
3
|
Balazs Z, Ivankovic I, Balermpas P, Gitchev T, Willmann J, Krauthammer M, Andratschke N. Abstract LB112: Liquid biopsy monitoring reveals high molecular weight cfDNA fragments associated with radiotherapy dose-intensity. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-lb112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Radiotherapy aims at delivering a high dose of radiation to a tumor while minimizing the dose absorbed by healthy tissues, minimizing side effects or toxicities. Radiotherapy monitoring currently largely relies on longitudinal imaging with spatial and limited functional information on therapy response. Particularly, discrimination of radiotherapy effect on the tumor versus healthy tissue can be challenging and imaging response may lag behind actual response on the tumor cell level. Liquid biopsy monitoring promises to complement imaging by providing systemic biological information about the effects of radiotherapy. Cell-free DNA (cfDNA) in the blood plasma contains genetic and epigenetic information about cell death processes, and cfDNA monitoring may thus lend itself to observing both tumor response and normal-tissue toxicity during radiotherapy.
Methods: Seven polymetastatic patients, seven healthy volunteers, seven oligometastatic patients (OMD) and seven head-and neck cancer patients (H&N) were recruited for the study. OMD patients received stereotactic body radiation therapy in 5 fractions of 5-10 Gy, heterogeneously prescribed, while H&N underwent homogeneously 2 Gy radiation to a total dose of 70 Gy. Blood samples were collected from all patients at baseline and from patients undergoing radiotherapy twice during and twice after treatment, with samples collected up to six months after treatment. cfDNA was isolated and low-pass (7x) whole-genome sequencing was performed to examine fragment-length distribution and copy number alterations. We applied in silico size selection for 90 to 150 bp long fragments to improve copy number variant detection. Clinical measures and imaging findings were compared to cfDNA fragment analysis.
Results: Samples showing high circulating tumor DNA content in copy number analysis (tMAD>0.03) also showed a higher proportion of short fragments (80-100 bp) compared to the samples of healthy individuals (ANOVA: p=0.0216, Tukey-pairwise: p=0.0287), whereas samples with low circulating tumor content did not (Tukey-pairwise: p=0.7540). We observed rapidly declining tumor fraction under treatment in a patient with prostate cancer and a high tMAD value at baseline. However, in the follow-up sample, residual tumor was detectable in the cfDNA copy number analysis, which was further confirmed by increasing PSA values. We observed a significant increase in the fraction of fragments between 200 and 250 bp in response to the treatment in oligometastatic patients receiving high-intensity radiotherapy, which returned to baseline in the follow-up measurements (ANOVA: p=0.0252, Tukey-pairwise: p=0.3138). A similar trend was observable (ANOVA: p=0.37) in head-and-neck patients, who received lower fractions of radiotherapy.
Conclusions: Applying low-pass whole-genome cfDNA-sequencing, we were able to monitor radiotherapy response in oligometastatic and head-and-neck cancer patients. We have also observed short-term increase in the number fragments between 200 and 250 bp during treatment, which we hypothesize to be a necrotic signal. The minimal invasive nature and the relatively low cost of low-pass cfDNA-sequencing makes it a viable method for frequent monitoring, which may allow prediction of tumor response and patient outcome.
Citation Format: Zsolt Balazs, Ivna Ivankovic, Panagiotis Balermpas, Todor Gitchev, Jonas Willmann, Michael Krauthammer, Nicolaus Andratschke. Liquid biopsy monitoring reveals high molecular weight cfDNA fragments associated with radiotherapy dose-intensity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB112.
Collapse
|